Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, 7 to 17 year old (inclusive) at the time of signing consent~* meets DSM-IV-TR diagnostic criteria for Tourette's Disorder~* Presenting tic symptoms cause impairment in the subject's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships~* Females of childbearing potential must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception and must not be pregnant or lactating~* Written informed consent obtained from a legally acceptable representative \& informed assent at Screening as applicable by trial center's IRB/IEC~* The subject, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator~Exclusion Criteria:~* Clinical presentation and/or history, consistent with another neurologic condition that may have accompanying abnormal movements~* History of schizophrenia, bipolar disorder, or other psychotic disorder~* Subject receiving psychostimulants for treatment of ADD/ADHD and who have developed and/or had exacerbations of tic disorder after initiation of stimulant treatment~* Currently meets DSM-IV-TR criteria for a primary mood disorder~* Severe Obsessive Compulsive Disorder (OCD)~* Taken aripiprazole within 30 days of the Screening visit~* Received any investigational agent in a clinical trial within 30 days prior to Screening, enrolled in studies 31-12-272, 31-12-273, 31-12-274; or who were randomized into a clinical trial with Once-daily aripiprazole at any time~* History of neuroleptic malignant syndrome~* Sexually active patients not using 2 approved methods of contraception~* Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug)~* Risk of committing suicide~* Body weight lower than 16 kg~* Taken neuroleptic or antiparkinson drugs \< 14 days prior to randomization~* Requiring cognitive behavioral therapy (CBT) for Tourette's during trial~* Subject meets DSM-IV-TR criteria for any significant psychoactive substance use disorder within the past 3 months~* Positive drug screen~* Subject requires medications not allowed per protocol~* Use of CYP2D6 and CYP3A4 inhibitors or CYP3A4 inducers within 14 days prior to dosing and for duration of trial~* Use of herbal medications of any kind and nutritional or dietary supplements for Tourette's disorder within 7 days prior to dosing and for the duration of the trial~* Inability to swallow tablets or tolerate oral medication~* Abnormal laboratory test results, vital signs and ECG results

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Once-Daily
- Aripiprazole 5 mg or 10 mg (Type: EXPERIMENTAL): Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
- Aripiprazole 10 mg or 20 mg (Type: EXPERIMENTAL): Aripiprazole 10 mg 20 mg Immediate Release Once-Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).